Kaitlin J. Mayne

Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA).

2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA).

Journal: European heart journal

Published: August 28, 2026

"Hi"s and "Lo"s of Targeting Serum Phosphate Levels in Hemodialysis.

"Hi"s and "Lo"s of Targeting Serum Phosphate Levels in Hemodialysis.

Journal: Journal of the American Society of Nephrology : JASN

Published: October 30, 2025

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: June 18, 2025

Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study.

Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study.

Journal: European journal of preventive cardiology

Published: May 19, 2025

Increased risk of cardiac death with cumulative exposure to fluid overload and dialysate sodium ≤138 mmol/l in hemodialysis patients.

Increased risk of cardiac death with cumulative exposure to fluid overload and dialysate sodium ≤138 mmol/l in hemodialysis patients.

Journal: Clinical kidney journal

Published: March 03, 2025

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Journal: EClinicalMedicine

Published: February 18, 2025

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Journal: The New England journal of medicine

Published: October 25, 2024

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 15, 2024

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 04, 2024

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: April 16, 2024

Associations of Abnormal Fluid Status, Plasma Sodium Disorders, and Low Dialysate Sodium with Mortality in Patients on Hemodialysis.

Associations of Abnormal Fluid Status, Plasma Sodium Disorders, and Low Dialysate Sodium with Mortality in Patients on Hemodialysis.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 29, 2024

Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.

Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.

Journal: Diabetes, obesity & metabolism

Published: March 29, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026